Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PLD+C+HP vs TCbHP in HER2+ Breast Cancer
NCT05159193Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin in HER2-positive breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Dec 2021; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05159193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159193.